Gamma amino beta-hydroxybutyric acid

Gamma-Amino-Beta-Hydroxybutyric Acid (GABOB)

1. Identity and Chemical Characterization

Names and Synonyms

γ-Amino-β-hydroxybutyric acid (GABOB), also known as β-hydroxy-γ-aminobutyric acid (β-hydroxy-GABA), is sold under the brand name Gamibetal among others. The compound is also encountered in the scientific literature under the systematic IUPAC name 4-amino-3-hydroxybutanoic acid, as well as a range of synonyms documented in chemical registries: (±)-4-amino-3-hydroxybutyric acid, 3-hydroxy-4-aminobutyric acid, 3-hydroxy-GABA, DL-4-amino-3-hydroxybutanoic acid, β-hydroxy-GABA, and β-hydroxy-γ-aminobutyric acid.

GABOB has been referred to by the generic name buxamine or buxamina. GABOB is sold primarily under the brand name Gamibetal, and has also been marketed under a variety of other brand names including Aminoxan, Bogil, Diastal, Gabimex, Gabomade, Gaboril, Gamalate, and Kolpo.

Structural Relationships

GABOB is a GABA analogue, or an analogue of the neurotransmitter γ-aminobutyric acid (GABA), and has been found to be an endogenous metabolite of GABA. GABOB, or β-hydroxy-GABA, is a close structural analogue of GABA, as well as of γ-hydroxybutyric acid (GHB), phenibut (β-phenyl-GABA), baclofen (β-(4-chlorophenyl)-GABA), and pregabalin (β-isobutyl-GABA). Structurally, GABOB differs from GABA solely by the addition of a hydroxyl group at the beta (3) carbon position of the four-carbon backbone.

Stereoisomers

GABOB has two stereoisomers and shows stereoselectivity in its actions. Specifically, (R)-(–)-GABOB is a moderate-potency agonist of the GABA_B receptor, while (S)-(+)-GABOB is a partial agonist of the GABA_B receptor and an agonist of the GABA_A receptor. (S)-(+)-GABOB is around twice as potent an anticonvulsant as (R)-(–)-GABOB. GABOB is used medically as a racemic mixture.

Molecular Formula and Registration

GABOB has the molecular formula C₄H₉NO₃ and CAS registry numbers including 352-21-6 (DL-racemate) and 924-49-2. GABOB is also an endogenous active metabolite and analogue of the neurotransmitter γ-aminobutyric acid (GABA), and for this reason may function as a neurotransmitter itself.

Endogenous Occurrence

GABOB is found naturally in the human body, but it is not known whether it has an important physiological role at normal concentrations. In vivo experiments using monoamine oxidase or diamine oxidase inhibitors suggested the participation of both enzymes in the formation of GABOB from 2-hydroxyputrescine in rat organs other than the brain, where diamine oxidase appeared to play the major role. Time course experiments suggested that the anticonvulsant effect of 2-hydroxyputrescine depended on the formation of gamma-amino-beta-hydroxybutyric acid from 2-hydroxyputrescine in the rat brain.

Pharmaceutical Forms and Preparations

GABOB has been prepared and administered in several forms in medical and research contexts. Clinical epilepsy studies from Japan in the early 1960s employed oral administration. A 1982 clinical endocrinology study by Melis et al. (referenced in Melis GB et al., "Dose-related effects of gamma-amino beta-hydroxy butyric acid (GABOB) infusion on growth hormone secretion in normal women," J Endocrinol Invest, 1982) used intravenous infusion. Early Japanese neurosurgical investigations also explored intraspinal injection. Oxiracetam (4-hydroxy-2-oxo-1-pyrrolidine acetamide), a derivative of cyclic gamma-amino-beta-hydroxybutyric acid (GABOB), selectively acts on the cerebral cortex and hippocampus to protect, activate and promote nerve cell function. In dietary supplement markets, GABOB is typically sold in capsule or tablet form as the DL-racemate.

2. Traditional and Historical Use

Origins of Medical Investigation

GABOB does not originate from an ethnobotanical or herbal tradition; it was identified as a neurochemical entity in the context of mid-twentieth century neurophysiology. Its medicinal investigation arose directly from research into endogenous brain inhibitory amino acids. The earliest documented clinical investigations date to the late 1950s and early 1960s, primarily in Japan and Italy, where neurologists and psychiatrists explored GABA-related compounds as potential antiepileptic agents.

Clinical experience with gamma-amino-beta-hydroxybutyric acid in epileptics was reported by Wada T, Goto A, Sato K, Fukushima Y, published in Sogo Igaku in May 1962. Italian publications from the same era explored GABA and GABOB within the framework of "biological anti-epilepsy therapy." Modern orientations in the therapy of epilepsy were examined in the light of recent acquisitions regarding cerebral metabolism of gamma-amino-butyric acid (GABA) and gamma-amino-beta-hydroxybutyric acid (GABOB), published in Clin Ter in 1962 by De Maio D.

Wada and colleagues studied the effect of GABOB on 150 epileptics with various types of seizures in Japan, carried out in two groups: patients who had been given ordinary antiepileptic medication for a period of time and then had GABOB added, and patients given only GABOB from the beginning.

The early Italian research by De Maio and Pasquariello, published in Psychopharmacologia in 1963, explored the relationship between gamma-amino-beta-hydroxybutyric acid (GABOB) and brain serotonin. This body of Italian and Japanese research formed the scientific foundation for GABOB's eventual use as a registered pharmaceutical in Europe, Japan, and Mexico.

Regulatory and Pharmaceutical History

GABOB is an anticonvulsant used for the treatment of epilepsy in Europe, Japan, and Mexico. It was subsequently adopted as a dietary supplement in some markets, particularly in the United States, where it is not approved as a pharmaceutical drug. Its effectiveness for purposes such as improving learning, memory, and growth hormone release has not been well established, and it is not widely used in medicine, although it is sold as a dietary supplement.

3. Key Constituents, Active Compounds, and Mechanisms of Action

Receptor Pharmacology

GABOB is a GABA receptor agonist. It has two stereoisomers and shows stereoselectivity in its actions. Specifically, (R)-(–)-GABOB is a moderate-potency agonist of the GABA_B receptor, while (S)-(+)-GABOB is a partial agonist of the GABA_B receptor and an agonist of the GABA_A receptor.

Understanding the significance of these receptor targets requires context: GABA is the major inhibitory neurotransmitter in the central nervous system, acting via stimulation of GABA_A, GABA_B, and GABA_C receptors. GABA_A and GABA_C receptors are coupled to chloride ion channels and mediate fast synaptic inhibition. GABA_B receptors are coupled through G proteins to neuronal potassium and calcium channels and mediate slow synaptic inhibition by increasing potassium and decreasing calcium conductance.

Postsynaptic GABA_B receptors activate inwardly rectifying potassium channels. Activation of presynaptic GABA_B receptors, acting as heteroreceptors or autoreceptors, causes an inhibition of neurotransmitter release by depressing Ca²⁺ influx via calcium channels. GABOB's agonism at both receptor types, albeit with different stereoisomers, underlies its observed central nervous system inhibitory actions.

Central Nervous System Potency Relative to GABA

Relative to GABA, GABOB has more potent inhibitory effects on the central nervous system, perhaps due to its greater capacity to cross the blood–brain barrier. This is pharmacologically significant because GABA itself, when taken orally, does not readily enter the brain. GABOB's structural modification—the addition of the beta-hydroxyl group—appears to facilitate this penetration, making GABOB a more centrally active compound per unit dose relative to GABA.

Anticonvulsant Mechanism

The anticonvulsant action of gamma-amino-beta-hydroxybutyric acid involves the stimulation of Cl⁻ influx plus the inhibition of GABA uptake into brain membrane vesicles. Stimulation of chloride influx is consistent with GABA_A receptor activation, which hyperpolarizes neurons and reduces their tendency to fire. Inhibition of GABA reuptake would prolong GABAergic inhibitory tone in the synapse. Together these mechanisms converge on enhanced GABAergic inhibition in neuronal circuits underlying seizure generation.

GABOB has anticonvulsant properties, but is of relatively low potency when used by itself, and is more useful as an adjuvant treatment used alongside another anticonvulsant drug.

Growth Hormone Axis

Animal research has documented GABOB's influence on the hypothalamic–pituitary axis. Effects of gamma-aminobutyric acid (GABA) and gamma-amino-β-hydroxybutyric acid (GABOB) on growth hormone (GH) release were investigated in the urethane-anesthetized male rat. An intraventricular injection of GABA and L-GABOB but not D-GABOB caused a significant increase in plasma GH. An intravenous injection of L-GABOB, at the dose which had no significant effect on basal plasma GH, remarkably enhanced plasma GH response to pentobarbital. These results suggest that GABA and L-GABOB stimulate GH release possibly via the central nervous system in the rat.

This stereoselectivity—with L-GABOB but not D-GABOB stimulating GH—is notable and consistent with the broader finding that the two enantiomers have distinct receptor profiles and biological activities. The exact hypothalamic mechanism for GH stimulation has not been fully characterized but is generally attributed to GABAergic input to somatostatin-producing neurons or direct effects on growth hormone-releasing hormone neurons.

Serotonin Modulation

Gamma-amino-beta-hydroxybutyric acid (GABOB), injected intraperitoneally in rats at the dose of 0.5 g/kg, causes a significant decrease of brain serotonin, and proves different from other anticonvulsant drugs in this respect. The significance of this serotonin-lowering effect in the context of GABOB's anticonvulsant action or other claimed benefits is not well characterized in subsequent literature.

Cholinergic and Cognitive Mechanisms

Studies have suggested GABOB may produce improved learning and memory function, probably through a cholinergic mechanism. The preclinical research underlying this claim was conducted with cyclic GABA-GABOB analogues (e.g., Banfi et al., Farmaco Sci, 1984). GABOB's structural relationship to oxiracetam—a nootropic drug—is also relevant: oxiracetam (4-hydroxy-2-oxo-1-pyrrolidine acetamide) is a derivative of cyclic gamma-amino-beta-hydroxybutyric acid (GABOB), and selectively acts on the cerebral cortex and hippocampus to protect, activate and promote nerve cell function.

4. Scientific Evidence by Area of Use

4.1 Epilepsy and Seizure Disorders

Historical Clinical Evidence (Japan, 1961–1964)

The most substantial body of clinical literature on GABOB concerns its use in epilepsy treatment, concentrated in Japanese and Italian publications from the early 1960s. Wada and colleagues studied the effect of GABOB on 150 epileptics with various types of seizures, carried out in two groups—old cases and new ones. In 99 old cases with a total of 116 seizures, the effect of the medication prior to GABOB was increased for 22%, unchanged for 48%, and reduced for 30%.

GABOB represented prominent effects in 26 new cases with 28 seizures: 50% were completely controlled and 25% showed certain improvements. GABOB was reported to be most effective for seizures of convulsive type and for children. The optimal dose was estimated as 1.0–1.5 g daily for adults and 0.5–1.0 g for children, but the effect cannot be ascertained immediately. No marked side effects were noticed; however, the effect of GABOB showed great individual variation.

A synergistic effect between GABOB and other antiepileptic drugs appeared to be little. Intraspinal administration was also explored: a 1964 paper published in Folia Psychiatrica et Neurologica Japonica by Nishimoto, Mori, Takashita, and Namba reported on treatment of epilepsy by intraspinal injection of GABOB.

Evidence Strength Assessment: Epilepsy

The clinical evidence for GABOB in epilepsy is historically important but methodologically limited by modern standards. The available studies are non-randomized, conducted without control arms, used heterogeneous patient populations, and were published primarily without accessible full-text English-language abstracts. GABOB is of relatively low potency as an anticonvulsant when used by itself, and is more useful as an adjuvant treatment used alongside another anticonvulsant. No modern randomized controlled trials (RCTs) comparing GABOB to current standard-of-care antiepileptic drugs have been identified in the peer-reviewed literature. The evidence base is therefore to be considered preliminary and historically dated.

4.2 Growth Hormone Secretion

Preclinical Evidence

The rat study by Abe et al. (Endocrinol Jpn, 1977), cited in multiple reviews, found that intraventricular injection of L-GABOB, but not D-GABOB, significantly increased plasma growth hormone in anesthetized rats. This stereoselectivity indicates a specific receptor-mediated mechanism rather than a nonspecific effect.

Human/Clinical Evidence

A 1982 human study by Melis and colleagues (J Endocrinol Invest, 5(2):101–106, 1982; PMID 7096918) examined dose-related effects of GABOB infusion on growth hormone secretion in normal women. The study, "Dose-related effects of gamma-amino beta-hydroxy butyric acid (GABOB) infusion on growth hormone secretion in normal women," was published in the Journal of Endocrinological Investigation, volume 5, number 2, pages 101–106 (doi: 10.1007/BF03350499, PMID 7096918). The results of this human study demonstrated a dose-related relationship between GABOB infusion and GH secretion, consistent with the earlier rat data. However, this was a single small study using intravenous infusion—not an oral dose—and was not replicated in larger controlled trials.

Evidence Strength Assessment: Growth Hormone

Evidence that GABOB stimulates growth hormone release consists of one small human clinical study using intravenous infusion, supported by animal (rat) mechanistic data. The evidence is preliminary: no oral dose-ranging studies in humans, no studies assessing functional anabolic outcomes, and no replication in independent cohorts have been identified. While studies have suggested GABOB may boost growth hormone release, its effectiveness for these purposes has not been well established and it is not widely used in medicine.

4.3 Learning and Memory

Preclinical Evidence

The putative cognitive effects of GABOB are derived primarily from preclinical investigations of cyclic GABA-GABOB analogues. Banfi et al. (Farmaco Sci, 1984, Jan;39(1):16–22, PMID 6538512) studied activity on learning and memory of cyclic GABA-GABOB analogues in animal models. These analogues—rather than GABOB itself—formed the basis for subsequent pharmacological development of compounds such as oxiracetam. Oxiracetam, a derivative of cyclic gamma-amino-beta-hydroxybutyric acid (GABOB), is mainly used for cognitive impairment caused by mild to moderate vascular dementia, mixed dementia, neurodegenerative diseases, and brain trauma, improving learning ability and enhancing memory in clinical practice.

Studies have suggested GABOB may produce improved learning and memory function, probably through a cholinergic mechanism. The cholinergic hypothesis for GABOB's cognitive effects proposes that enhanced GABAergic tone modulates acetylcholine release in hippocampal and cortical circuits relevant to memory formation.

Evidence Strength Assessment: Cognition

There are no published human clinical trials specifically examining the effects of GABOB itself (as opposed to its cyclic analogues) on learning or memory outcomes. The evidence is animal/preclinical only for GABOB per se. The related compound oxiracetam has been evaluated clinically for dementia, but these findings cannot be directly attributed to GABOB.

4.4 Relationship to Oxiracetam and Nootropic Research

Oxiracetam (4-hydroxy-2-oxo-1-pyrrolidine acetamide) is a derivative of cyclic gamma-amino-beta-hydroxybutyric acid (GABOB), selectively acts on the cerebral cortex and hippocampus to protect, activate and promote nerve cell function, while oxiracetam itself has no direct vascular activity and no central excitatory effect, and the effect on learning and memory ability is a lasting promoting effect. Oxiracetam is mainly used for cognitive impairment caused by mild to moderate vascular dementia, mixed dementia, neurodegenerative diseases, brain trauma, and other diseases, improving learning ability and enhancing memory in clinical practice. These clinical findings for oxiracetam are sometimes cited in the context of GABOB, but care must be taken not to conflate the pharmacology of GABOB with that of its cyclic derivatives, as the compounds differ substantially in structure and mechanism.

5. Body Systems and Health Areas of Association

Central Nervous System (Inhibitory Neurotransmission)

GABOB's primary pharmacological activity is in the CNS. As a dual GABA_A/_B receptor agonist, it participates in enhancing GABAergic inhibitory neurotransmission. Relative to GABA, GABOB has more potent inhibitory effects on the central nervous system, perhaps due to its greater capacity to cross the blood–brain barrier. This CNS penetration is the key differentiating feature from GABA itself and the basis for its clinical utility in epilepsy.

Neuroendocrine System (Hypothalamic–Pituitary–GH Axis)

GABOB has been associated with stimulation of growth hormone release via central GABAergic pathways. An intraventricular injection of GABA and L-GABOB but not D-GABOB caused a significant increase in plasma GH in rats. An intravenous injection of L-GABOB remarkably enhanced plasma GH response to pentobarbital. These results suggest that GABA and L-GABOB stimulate GH release possibly via the central nervous system.

Hippocampus and Cognitive Circuits

Based on preclinical data and the relationship to oxiracetam, GABOB and its cyclic analogues are associated with hippocampal and cortical circuits governing learning and memory. Studies have suggested GABOB may produce improved learning and memory function, probably through a cholinergic mechanism. The cholinergic system of the basal forebrain projects extensively to the hippocampus and prefrontal cortex, areas known to be central to declarative memory.

Serotonergic System

GABOB (injected intraperitoneally in rats at 0.5 g/kg) causes a significant decrease of brain serotonin, and proves different from other anticonvulsant drugs in this respect. The physiological implications of this serotonin reduction—distinct from the GABA-mimetic effects of other anticonvulsants—have not been thoroughly characterized.

6. Dosage Forms and Reported Dosages

Epilepsy (Oral Administration, Historical Clinical Studies)

The optimal dose of GABOB was estimated as 1.0–1.5 g daily for adults and 0.5–1.0 g for children, but the effect cannot be ascertained immediately. These figures are derived from the Wada et al. (1961) study of 150 Japanese epileptic patients and represent the only available human oral dosing data for the compound in a clinical setting.

Growth Hormone Stimulation (Intravenous Infusion, Human Study)

The 1982 study by Melis et al. administered GABOB by intravenous infusion to assess dose-related effects on GH secretion in normal women. The study documented dose-dependent GH responses, though the specific infusion doses and the precise GH levels recorded are not available in freely accessible abstracts.

Animal Studies

GABOB was injected intraperitoneally in rats at the dose of 0.5 g/kg to produce a significant decrease of brain serotonin. In seizure threshold studies, the threshold of pentylenetetrazol-induced generalized convulsions was measured in rats after the intraventricular injection of 2-hydroxyputrescine (the precursor from which GABOB is formed endogenously in brain tissue).

Supplement Market

GABOB is sold in dietary supplement formulations, typically in capsule or tablet form. No peer-reviewed study establishing an effective oral dose in healthy humans for any of the supplement-marketed indications (sleep, stress, cognitive function) has been identified in the available scientific literature. Dosing information found on commercial supplement products is not sourced from controlled clinical trials and is therefore not reported here.

7. Safety Considerations and Drug Interactions

Tolerability in Clinical Epilepsy Trials

No marked side effects were noticed in the Wada et al. clinical series of 150 epileptic patients; however, the effect of GABOB showed great individual variation. This single historical observation is the primary direct human tolerability data available for GABOB. The study did not employ systematic adverse event monitoring by modern pharmacovigilance standards.

Comparisons with the GABA Safety Profile

Because GABOB is a close structural analogue and metabolite of GABA, the USP safety review of GABA provides relevant comparative context. Data showed no serious adverse events associated with GABA at intakes up to 18 g/d for 4 days and in longer studies at intakes of 120 mg/d for 12 weeks. Some studies showed that GABA was associated with a transient and moderate drop in blood pressure (<10% change). No studies were available on effects of GABA during pregnancy and lactation, and no case reports or spontaneous adverse events associated with GABA were found.

Hypotension Risk

Because some studies showed that GABA was associated with decreases in blood pressure, it is conceivable that concurrent use of GABA with anti-hypertensive medications could increase the risk of hypotension. By pharmacological analogy, GABOB—sharing GABA_A and GABA_B agonist properties—may carry a similar potential for blood pressure reduction, particularly in combination with antihypertensive drugs. This has not been specifically evaluated for GABOB in published studies.

Pregnancy and Lactation

Caution is advised for pregnant and lactating women since GABA can affect neurotransmitters and the endocrine system, including increases in growth hormone and prolactin levels. These considerations, established for GABA by the USP review, are plausibly applicable to GABOB given its structural and mechanistic similarity, but no specific safety data for GABOB in pregnancy or lactation has been identified.

CNS Depressant Interactions

GABOB's mechanism as a CNS depressant via GABAergic agonism creates a theoretical basis for additive or synergistic interactions with other CNS depressants, including benzodiazepines, barbiturates, opioids, and alcohol. No formal drug interaction studies for GABOB have been identified in the published clinical literature. GABOB is of relatively low potency as an anticonvulsant when used by itself, and is more useful as an adjuvant treatment used alongside another anticonvulsant—a context which implies historical clinical co-administration. No adverse interaction events from such adjuvant use were reported in the available historical literature, but systematic data are absent.

Regulatory Status

GABOB is an anticonvulsant used for the treatment of epilepsy in Europe, Japan, and Mexico. In the United States, GABOB is not approved as a pharmaceutical drug; it is available as a dietary supplement and is not subject to pre-market safety review by the FDA in that capacity. No monograph for GABOB appears in the current USP, European Pharmacopoeia, or WHO monograph series.

8. Overall Evidence Summary

GABOB occupies an unusual position as a naturally occurring endogenous compound, a registered pharmaceutical in several countries, and a marketed dietary supplement in others. Its pharmacological properties as a GABA_A/GABA_B receptor agonist with enhanced CNS penetration relative to GABA are well-characterized in vitro and in animal models. Its anticonvulsant activity has been demonstrated in both preclinical seizure models and historical uncontrolled clinical series from the 1960s. Its effects on growth hormone secretion are supported by one small human infusion study and corroborating animal data. Its purported benefits for learning, memory, and general wellness rest on animal studies of cyclic analogues and a plausible but unverified cholinergic mechanism. No modern randomized controlled trials have been conducted for any indication. The totality of human clinical evidence for GABOB is therefore best described as historically documented but methodologically limited, and no claim of efficacy at commercially marketed supplement doses can be verified against published controlled trial data.

References

• Wikipedia: gamma-Amino-beta-hydroxybutyric acid
• WikiDoc: Gamma-amino-beta-hydroxybutyric acid
• ChemSpider: DL-γ-Amino-β-hydroxybutyric acid — structural identifiers and synonyms
• DrugBank: Gamma-amino-beta-hydroxybutyric acid — uses, interactions, mechanism of action
• PubMed: Formation of GABOB from 2-hydroxyputrescine and its anticonvulsant effect (1991)
• PubMed: GABOB treatment in epilepsy (search result cluster, Wada et al. 1961/1964)
• Wiley Online Library: GABOB treatment in epilepsy — Wada et al., Psychiatry and Clinical Neurosciences (1961)
• Springer: Gamma-amino-beta-hydroxybutyric acid (GABOB) and brain serotonin — De Maio & Pasquariello, Psychopharmacologia (1963)
• PubMed: GABA and GABOB in the perspective of biological anti-epilepsy therapy (1962 search result cluster)
• ResearchGate: Effect of GABA and GABOB on growth hormone and prolactin secretion (Abe et al., Endocrinol Jpn, 1977; Melis et al., 1982)
• HandWiki: Chemistry — Gamma-Amino-beta-hydroxybutyric acid
• ScienceDirect: Safety, tolerability, and pharmacokinetics of oral (S)-oxiracetam — GABOB as cyclic precursor (2023)
• PMC / Nutrients: United States Pharmacopeia (USP) Safety Review of Gamma-Aminobutyric Acid (GABA) (2021)
• USPTO Patent 8344028: Gamma-amino-butyric acid derivatives as GABAB receptor ligands